目的：探讨劳拉西泮治疗乳腺癌患者化疗后焦虑抑郁的应用价值及对生活质量的影响。方法200例乳腺癌化疗患者，采用简单随机分组的方法，对照组（n =100）应用常规止吐方案：托烷司琼5 mg，地塞米松5~10 mg 化疗第1天，地塞米松持续应用第2天和第3天。治疗组（n =100）应用常规止吐方案，加用劳拉西泮：劳拉西泮0.5~2.0 mg，每日2次口服，连用3天。治疗前后对患者应用焦虑和抑郁自评量表（SAS、SDS）进行评分，应用肿瘤患者的生活质量评分表（QOL）对患者进行评定。观察两组患者化疗后经上述治疗后焦虑抑郁、生活质量的改善情况。结果应用劳拉西泮联合常规止吐治疗方案，治疗后焦虑、抑郁与对照组的疗效比较，治疗组明显高于对照组，差异有统计学意义（ P<0.05）；生活质量方面：治疗组在食欲、精神、睡眠、疲乏、家庭理解与配合、同事的理解与配合（包括领导）、对治疗的态度、日常生活、治疗的副作用、面部表情共10项的评分明显高于对照组，差异有统计学意义（ P <0.05）。结论劳拉西泮可明显减少乳腺癌化疗患者焦虑、抑郁的发生，并可明显改善化疗后焦虑、抑郁情绪，通过改善患者焦虑抑郁情绪结合止吐方案，治疗恶心、呕吐疗效明显；生活质量得到显著改善。%Objective To explore the application value of lorazepam for the treatment of anxiety and depression and its influence on quali-ty of life in breast cancer patients who received chemotherapy. Methnds A total of 200 chemotherapy - treated breast cancer patients were divided into control group(n = 100)and treatment group(n = 100). The control group treated with conventional antiemetic regimen:tropisetron 5mg and dexamethasone 10mg on the first day of chemotherapy;dexamethasone continued for the second and third days of chemotherapy. Besides conven-tional antiemetic regimen,the treatment group received lorazepam 0. 5 ~ 2. 0 mg orally 2 times a day,for 3 days. Before and after the treatment, patients were evaluated with Self - Rating Anxiety Scale(SAS),Self - rating Depression Scale(SDS),and quality of life score(QOL)for pa-tients with tumor. The results were compared between two groups after chemotherapy. Results The treatment was more effective in treatment group than control group for anxiety and depression,the difference was statistically significant( P < 0. 05). The QOL scores of treatment group was significantly higher than the control group,the difference was statistically significant( P < 0. 05). Cniclusini Lorazepam can significantly reduce the occurrence and the level of anxiety and depression in breast cancer patients receiving chemotherapy and significantly improve the quality of the patients.
展开▼
